{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T22:25:07Z","timestamp":1794435907162,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T00:00:00Z","timestamp":1665187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["62131009"],"award-info":[{"award-number":["62131009"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81874120"],"award-info":[{"award-number":["81874120"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Non-inflamed tumors, including immune-excluded and immune-desert tumors, are commonly resistant to anti-PD-1\/PD-L1 (\u03b1-PD-1\/PD-L1) therapy. Our previous study reported the potent antitumor activity of anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 in immune-excluded tumors. However, YM101 had limited antitumor activity in immune-desert models. MSA-2 is a novel oral stimulator of interferon genes (STING) agonist, which activates the innate immune system and may synergize with YM101 in overcoming immunotherapy resistance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The dose-dependent effect of MSA-2 on STING signaling was determined by interferon-\u03b2 level. The maturation and function of dendritic cell (DC) were measured by flow cytometry, RNA-seq, one-way mixed lymphocyte reaction (MLR), OVA peptide pulse, and cytokine\/chemokine detection. The synergistic effect between MSA-2 and YM101 was assessed by one-way MLR. The macrophage activation was measured by flow cytometry and cytokine\/chemokine detection. The in vivo antitumor activity of MSA-2 combined with YM101 was explored in syngeneic murine tumor models. After treatments, the alterations in the tumor microenvironment (TME) were detected by flow cytometry, immunohistochemistry staining, immunofluorescence staining, RNA-seq, and single-cell RNA-seq (scRNA-seq).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>MSA-2 could promote the maturation and antigen presentation capability of murine DC. In the one-way MLR assay, MSA-2 synergized with YM101 in enhancing naive T cell activation. Moreover, MSA-2 stimulated the classical activation of macrophage, without significant influence on alternative activation. Further in vivo explorations showed that MSA-2 increased multiple proinflammatory cytokines and chemokines in the TME. MSA-2 combined with YM101 remarkedly retarded tumor growth in immune-excluded and immune-desert models, with superior antitumor activity to monotherapies. Flow cytometry, bulk RNA-seq, and scRNA-seq assays indicated that the combination therapy simultaneously boosted the innate and adaptive immunity, promoted antigen presentation, improved T cell migration and chemotaxis, and upregulated the numbers and activities of tumor-infiltrating lymphocytes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results demonstrate that MSA-2 synergizes with YM101 in boosting antitumor immunity. This immune cocktail therapy effectively overcomes immunotherapy resistance in immune-excluded and immune-desert models.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13045-022-01363-8","type":"journal-article","created":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T19:04:53Z","timestamp":1665255893000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Combination of oral STING agonist MSA-2 and anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors"],"prefix":"10.1186","volume":"15","author":[{"given":"Ming","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengke","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuze","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechao","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxiang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kongming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,8]]},"reference":[{"key":"1363_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"1363_CR2","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1084\/jem.20112741","volume":"209","author":"T Yokosuka","year":"2012","unstructured":"Yokosuka T, Takamatsu M, Kobayashi-Imanishi W, Hashimoto-Tane A, Azuma M, Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med. 2012;209:1201\u201317.","journal-title":"J Exp Med"},{"key":"1363_CR3","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L. A paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell. 2018;175:313\u201326.","journal-title":"Cell"},{"key":"1363_CR4","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","volume":"12","author":"A Akinleye","year":"2019","unstructured":"Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12:92.","journal-title":"J Hematol Oncol"},{"key":"1363_CR5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40364-020-00212-5","volume":"8","author":"JY Sun","year":"2020","unstructured":"Sun JY, Zhang D, Wu S, Xu M, Zhou X, Lu XJ, et al. Resistance to PD-1\/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives. Biomark Res. 2020;8:35.","journal-title":"Biomark Res"},{"key":"1363_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40164-021-00211-8","volume":"10","author":"M Niu","year":"2021","unstructured":"Niu M, Yi M, Li N, Luo S, Wu K. Predictive biomarkers of anti-PD-1\/PD-L1 therapy in NSCLC. Exp Hematol Oncol. 2021;10:18.","journal-title":"Exp Hematol Oncol"},{"key":"1363_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u201330.","journal-title":"Nature"},{"key":"1363_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12943-019-1091-2","volume":"18","author":"S Qin","year":"2019","unstructured":"Qin S, Xu L, Yi M, Yu S, Wu K, Luo S. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol Cancer. 2019;18:155.","journal-title":"Mol Cancer"},{"key":"1363_CR9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40164-019-0143-z","volume":"8","author":"Z Qiu","year":"2019","unstructured":"Qiu Z, Chen Z, Zhang C, Zhong W. Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer. Exp Hematol Oncol. 2019;8:19.","journal-title":"Exp Hematol Oncol"},{"key":"1363_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","volume":"52","author":"PS Hegde","year":"2020","unstructured":"Hegde PS, Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335.","journal-title":"Immunity"},{"key":"1363_CR11","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22:1865\u201374.","journal-title":"Clin Cancer Res"},{"key":"1363_CR12","doi-asserted-by":"publisher","first-page":"5361","DOI":"10.1038\/s41467-018-07767-w","volume":"9","author":"Q Jia","year":"2018","unstructured":"Jia Q, Wu W, Wang Y, Alexander PB, Sun C, Gong Z, et al. Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. Nat Commun. 2018;9:5361.","journal-title":"Nat Commun"},{"key":"1363_CR13","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","volume":"9","author":"E Berglund","year":"2018","unstructured":"Berglund E, Maaskola J, Schultz N, Friedrich S, Marklund M, Bergenstr\u00e5hle J, et al. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun. 2018;9:2419.","journal-title":"Nat Commun"},{"key":"1363_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","volume":"11","author":"Q Jia","year":"2022","unstructured":"Jia Q, Wang A, Yuan Y, Zhu B, Long H. Heterogeneity of the tumor immune microenvironment and its clinical relevance. Exp Hematol Oncol. 2022;11:24.","journal-title":"Exp Hematol Oncol"},{"key":"1363_CR15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40164-020-00165-3","volume":"9","author":"F Liu","year":"2020","unstructured":"Liu F, Qin L, Liao Z, Song J, Yuan C, Liu Y, et al. Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma. Exp Hematol Oncol. 2020;9:10.","journal-title":"Exp Hematol Oncol"},{"key":"1363_CR16","doi-asserted-by":"publisher","first-page":"9527","DOI":"10.2147\/OTT.S224013","volume":"12","author":"X Bai","year":"2019","unstructured":"Bai X, Yi M, Jiao Y, Chu Q, Wu K. Blocking TGF-\u03b2 signaling to enhance the efficacy of immune checkpoint inhibitor. Onco Targets Ther. 2019;12:9527\u201338.","journal-title":"Onco Targets Ther"},{"key":"1363_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"BG Kim","year":"2021","unstructured":"Kim BG, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol. 2021;14:55.","journal-title":"J Hematol Oncol"},{"key":"1363_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.","journal-title":"Mol Cancer"},{"key":"1363_CR19","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"1363_CR20","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/nature25492","volume":"554","author":"DVF Tauriello","year":"2018","unstructured":"Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF\u03b2 drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554:538\u201343.","journal-title":"Nature"},{"key":"1363_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","volume":"14","author":"S Zhu","year":"2021","unstructured":"Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J Hematol Oncol. 2021;14:156.","journal-title":"J Hematol Oncol"},{"key":"1363_CR22","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Zhang J, Li A, Niu M, Yan Y, Jiao Y, et al. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1. J Hematol Oncol. 2021;14:27.","journal-title":"J Hematol Oncol"},{"key":"1363_CR23","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","volume":"14","author":"M Yi","year":"2021","unstructured":"Yi M, Niu M, Zhang J, Li S, Zhu S, Yan Y, et al. Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers. J Hematol Oncol. 2021;14:146.","journal-title":"J Hematol Oncol"},{"key":"1363_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13:143\u201358.","journal-title":"Nat Rev Clin Oncol"},{"key":"1363_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s40425-019-0573-5","volume":"7","author":"W Jing","year":"2019","unstructured":"Jing W, McAllister D, Vonderhaar EP, Palen K, Riese MJ, Gershan J, et al. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J Immunother Cancer. 2019;7:115.","journal-title":"J Immunother Cancer"},{"key":"1363_CR26","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res. 2020;30:966\u201379.","journal-title":"Cell Res"},{"key":"1363_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1038\/s41423-021-00669-w","volume":"18","author":"R Zhang","year":"2021","unstructured":"Zhang R, Wang C, Guan Y, Wei X, Sha M, Yi M, et al. Manganese salts function as potent adjuvants. Cell Mol Immunol. 2021;18:1222\u201334.","journal-title":"Cell Mol Immunol"},{"key":"1363_CR28","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13045-019-0721-x","volume":"12","author":"A Li","year":"2019","unstructured":"Li A, Yi M, Qin S, Song Y, Chu Q, Wu K. Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. J Hematol Oncol. 2019;12:35.","journal-title":"J Hematol Oncol"},{"key":"1363_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-020-00916-z","volume":"13","author":"M Jiang","year":"2020","unstructured":"Jiang M, Chen P, Wang L, Li W, Chen B, Liu Y, et al. cGAS-STING, an important pathway in cancer immunotherapy. J Hematol Oncol. 2020;13:81.","journal-title":"J Hematol Oncol"},{"key":"1363_CR30","doi-asserted-by":"publisher","first-page":"eaba6098","DOI":"10.1126\/science.aba6098","volume":"369","author":"BS Pan","year":"2020","unstructured":"Pan BS, Perera SA, Piesvaux JA, Presland JP, Schroeder GK, Cumming JN, et al. An orally available non-nucleotide STING agonist with antitumor activity. Science. 2020;369:eaba6098.","journal-title":"Science"},{"key":"1363_CR31","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1046\/j.1523-1747.2000.00084.x","volume":"115","author":"NA Kukutsch","year":"2000","unstructured":"Kukutsch NA, Rossner S, Austyn JM, Schuler G, Lutz MB. Formation and kinetics of MHC class I-ovalbumin peptide complexes on immature and mature murine dendritic cells. J Invest Dermatol. 2000;115:449\u201353.","journal-title":"J Invest Dermatol"},{"key":"1363_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1006\/meth.1999.0813","volume":"18","author":"G Wang","year":"1999","unstructured":"Wang G, Achim CL, Hamilton RL, Wiley CA, Soontornniyomkij V. Tyramide signal amplification method in multiple-label immunofluorescence confocal microscopy. Methods. 1999;18:459\u201364.","journal-title":"Methods"},{"key":"1363_CR33","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat Immunol. 2019;20:163\u201372.","journal-title":"Nat Immunol"},{"key":"1363_CR34","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1016\/j.cell.2020.11.009","volume":"183","author":"AE Ringel","year":"2020","unstructured":"Ringel AE, Drijvers JM, Baker GJ, Catozzi A, Garc\u00eda-Ca\u00f1averas JC, Gassaway BM, et al. Obesity shapes metabolism in the tumor microenvironment to suppress anti-tumor immunity. Cell. 2020;183:1848-66.e26.","journal-title":"Cell"},{"key":"1363_CR35","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2020.03.048","volume":"181","author":"L Zhang","year":"2020","unstructured":"Zhang L, Li Z, Skrzypczynska KM, Fang Q, Zhang W, O\u2019Brien SA, et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell. 2020;181:442-59.e29.","journal-title":"Cell"},{"key":"1363_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002809","volume":"9","author":"C Zhang","year":"2021","unstructured":"Zhang C, Lei L, Yang X, Ma K, Zheng H, Su Y, et al. Single-cell sequencing reveals antitumor characteristics of intratumoral immune cells in old mice. J Immunother Cancer. 2021;9: e002809.","journal-title":"J Immunother Cancer"},{"key":"1363_CR37","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/s41586-018-0130-2","volume":"557","author":"Y Simoni","year":"2018","unstructured":"Simoni Y, Becht E, Fehlings M, Loh CY, Koo SL, Teng KWW, et al. Bystander CD8(+) T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature. 2018;557:575\u20139.","journal-title":"Nature"},{"key":"1363_CR38","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.immuni.2020.05.001","volume":"52","author":"J Ni","year":"2020","unstructured":"Ni J, Wang X, Stojanovic A, Zhang Q, Wincher M, B\u00fchler L, et al. Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1\u03b1 unleashes NK cell activity. Immunity. 2020;52:1075-87.e8.","journal-title":"Immunity"},{"key":"1363_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks461","volume":"40","author":"D Wu","year":"2012","unstructured":"Wu D, Smyth GK. Camera: a competitive gene set test accounting for inter-gene correlation. Nucleic Acids Res. 2012;40: e133.","journal-title":"Nucleic Acids Res"},{"key":"1363_CR40","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"1363_CR41","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40425-018-0356-4","volume":"6","author":"RB Holmgaard","year":"2018","unstructured":"Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, et al. Targeting the TGF\u03b2 pathway with galunisertib, a TGF\u03b2RI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. J Immunother Cancer. 2018;6:47.","journal-title":"J Immunother Cancer"},{"key":"1363_CR42","doi-asserted-by":"publisher","first-page":"1824631","DOI":"10.1080\/2162402X.2020.1824631","volume":"9","author":"W Qin","year":"2020","unstructured":"Qin W, Zou J, Huang Y, Liu C, Kang Y, Han H, et al. Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice. Oncoimmunology. 2020;9:1824631.","journal-title":"Oncoimmunology"},{"key":"1363_CR43","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.4049\/jimmunol.1701675","volume":"201","author":"P Chaves","year":"2018","unstructured":"Chaves P, Zriwil A, Wittmann L, Boukarabila H, Peitzsch C, Jacobsen SEW, et al. Loss of Canonical notch signaling affects multiple steps in NK cell development in mice. J Immunol. 2018;201:3307\u201319.","journal-title":"J Immunol"},{"key":"1363_CR44","doi-asserted-by":"publisher","first-page":"3344","DOI":"10.4049\/jimmunol.1400534","volume":"193","author":"M Felices","year":"2014","unstructured":"Felices M, Ankarlo DE, Lenvik TR, Nelson HH, Blazar BR, Verneris MR, et al. Notch signaling at later stages of NK cell development enhances KIR expression and functional maturation. J Immunol. 2014;193:3344\u201354.","journal-title":"J Immunol"},{"key":"1363_CR45","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.trecan.2018.09.001","volume":"4","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Reis e Sousa C. The role of type 1 conventional dendritic cells in cancer immunity. Trends Cancer. 2018;4:784\u201392.","journal-title":"Trends Cancer."},{"key":"1363_CR46","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1093\/annonc\/mdw217","volume":"27","author":"JM Kim","year":"2016","unstructured":"Kim JM, Chen DS. Immune escape to PD-L1\/PD-1 blockade: seven steps to success (or failure). Ann Oncol. 2016;27:1492\u2013504.","journal-title":"Ann Oncol"},{"key":"1363_CR47","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21:184.","journal-title":"Mol Cancer"},{"key":"1363_CR48","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s13045-021-01218-8","volume":"14","author":"L Zhu","year":"2021","unstructured":"Zhu L, Liu J, Chen J, Zhou Q. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. J Hematol Oncol. 2021;14:206.","journal-title":"J Hematol Oncol"},{"key":"1363_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","volume":"21","author":"M Yi","year":"2022","unstructured":"Yi M, Zheng X, Niu M, Zhu S, Ge H, Wu K. Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions. Mol Cancer. 2022;21:28.","journal-title":"Mol Cancer"},{"key":"1363_CR50","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","volume":"37","author":"A Gardner","year":"2016","unstructured":"Gardner A, Ruffell B. Dendritic cells and cancer immunity. Trends Immunol. 2016;37:855\u201365.","journal-title":"Trends Immunol"},{"key":"1363_CR51","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40164-021-00252-z","volume":"10","author":"S Zhu","year":"2021","unstructured":"Zhu S, Yi M, Wu Y, Dong B, Wu K. Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies. Exp Hematol Oncol. 2021;10:60.","journal-title":"Exp Hematol Oncol"},{"key":"1363_CR52","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382.","journal-title":"Nat Rev Immunol"},{"key":"1363_CR53","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, Broz ML, Binnewies M, Headley MB, Nelson AE, Wolf DM, et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30:324\u201336.","journal-title":"Cancer Cell"},{"key":"1363_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF. The cytosolic DNA-Sensing cGAS-STING pathway in cancer. Cancer Discov. 2020;10:26\u201339.","journal-title":"Cancer Discov"},{"key":"1363_CR55","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12943-020-01247-w","volume":"19","author":"Y Wang","year":"2020","unstructured":"Wang Y, Luo J, Alu A, Han X, Wei Y, Wei X. cGAS-STING pathway in cancer biotherapy. Mol Cancer. 2020;19:136.","journal-title":"Mol Cancer"},{"key":"1363_CR56","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-021-01085-3","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Manochakian R, Zhao Y, Lou Y. Immunotherapies targeting stimulatory pathways and beyond. J Hematol Oncol. 2021;14:78.","journal-title":"J Hematol Oncol"},{"key":"1363_CR57","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1172\/JCI86892","volume":"126","author":"L Corrales","year":"2016","unstructured":"Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016;126:2404\u201311.","journal-title":"J Clin Invest"},{"key":"1363_CR58","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1158\/2159-8290.CD-20-0812","volume":"11","author":"SS Gu","year":"2021","unstructured":"Gu SS, Zhang W, Wang X, Jiang P, Traugh N, Li Z, et al. Therapeutically increasing MHC-I expression potentiates immune checkpoint blockade. Cancer Discov. 2021;11:1524\u201341.","journal-title":"Cancer Discov"},{"key":"1363_CR59","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","volume":"24","author":"J Strauss","year":"2018","unstructured":"Strauss J, Heery CR, Schlom J, Madan RA, Cao L, Kang Z, et al. Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF\u03b2, in advanced solid tumors. Clin Cancer Res. 2018;24:1287\u201395.","journal-title":"Clin Cancer Res"},{"key":"1363_CR60","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jtho.2020.03.003","volume":"15","author":"L Paz-Ares","year":"2020","unstructured":"Paz-Ares L, Kim TM, Vicente D, Felip E, Lee DH, Lee KH, et al. Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in second-line treatment of patients with NSCLC: results from an expansion cohort of a phase 1 trial. J Thorac Oncol. 2020;15:1210\u201322.","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-022-01363-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-022-01363-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,8]],"date-time":"2022-10-08T20:06:28Z","timestamp":1665259588000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-022-01363-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,8]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1363"],"URL":"https:\/\/doi.org\/10.1186\/s13045-022-01363-8","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,8]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal operations in this study were evaluated and approved by the Institutional Animal Care and Use Committee of Tongji Hospital of Huazhong University of Sciences and Technology.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JZ, YY, and PZ were employees of Wuhan YZY Biopharma Co., Ltd.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"142"}}